For people who feel overwhelmed by major lifestyle overhauls, this study offers a more practical message.

In a population cohort study of 59,078 UK Biobank participants, researchers found that adding about 5 minutes of sleep, nearly 2 minutes of moderate to vigorous physical activity, and a modest diet improvement such as half a serving of vegetables per day was associated with about 1 additional year of lifespan compared with people at the lowest baseline lifestyle levels.

The finding does not prove cause and effect, but it supports a realistic clinical idea: small gains across several habits may matter more than chasing perfection in one habit alone.

Study Details

Sleep, physical activity, and nutrition are usually discussed separately. A patient is told to sleep more, exercise more, or eat better. But real life does not work in separate boxes. These behaviors interact. Poor sleep can reduce activity. Low activity can worsen metabolic health. A poor diet can affect weight, inflammation, and cardiometabolic risk.

That is why this study is useful. Researchers looked at the combined effect of sleep, physical activity, and nutrition, described as SPAN behaviors. The study used UK Biobank participants, recruited between 2006 and 2010, with a median age of 64 years. The goal was to estimate the minimum combined improvements associated with longer lifespan and longer healthspan, meaning years lived without major chronic diseases such as cardiovascular disease, cancer, type 2 diabetes, COPD, and dementia.

What is the practical takeaway?

Modest combined changes may be more achievable than asking people to make one large lifestyle change at once. It also noted that a separate cardiovascular analysis found similarly small combined changes in sleep, activity, and diet were linked with lower risk for major cardiovascular events.

Methodology

This was a prospective cohort study, not a randomized clinical trial. That means researchers followed people over time and looked for associations between lifestyle patterns and outcomes.

A subsample of participants wore a wrist accelerometer for 7 days, which allowed researchers to estimate sleep duration and moderate to vigorous physical activity. Diet was assessed using a 10-item diet quality score that included foods such as vegetables, fruits, grains, meats, fish, dairy, oils, and sugar-sweetened beverages. Researchers then estimated lifespan and healthspan across different combinations of sleep, activity, and diet quality.

This is important for clinicians and patients to understand. The study can suggest that certain lifestyle patterns are associated with better outcomes, but it cannot prove that adding 5 minutes of sleep directly causes 1 extra year of life for every individual.

Key Findings

• People at the lowest baseline slept about 5.5 hours per night, did about 7.3 minutes of moderate activity daily, and had a diet quality score of 36 out of 100

• A minimum combined improvement of 5 minutes of sleep per day, 1.9 minutes of moderate to vigorous physical activity per day, and a 5-point diet quality score increase, such as half a serving of vegetables per day, was associated with 1 additional year of lifespan.

• The optimal lifestyle range in the study was 7.2 to 8.0 hours of sleep per day, more than 42 minutes of moderate to vigorous physical activity per day, and a diet quality score of 57.5 to 72.5. That combination was associated with about 9.35 additional years of lifespan and 9.45 additional years of healthspan compared with the least favorable lifestyle tertiles.

• For healthspan specifically, a combined improvement of 24 minutes of sleep, 3.7 minutes of moderate to vigorous activity, and a 23-point diet quality score increase was associated with about 4 additional disease-free years.

• A related cardiovascular analysis of more than 53,000 UK Biobank participants found that 11 more minutes of sleep, about 5 more minutes of exercise, and an extra quarter cup of vegetables were linked with about 10% lower risk of heart attack, stroke, and heart failure.

Implications for Practice

For patients, this study gives guidance to start smaller. The usual lifestyle advice can sound like a mountain: sleep 8 hours, exercise 150 minutes per week, eat a perfect diet, lose weight, reduce stress, and do all of it immediately. That message may be technically correct, but it can also be paralyzing.

This research suggests a different starting point. Add 5 minutes to sleep. Add a 2-minute brisk walk. Add half a serving of vegetables. These changes are not magic, and they are not a substitute for medical care, but they may help people build momentum. The real clinical value may be in moving people from zero progress to consistent progress.

For healthcare providers, the study supports a more flexible counseling model. Instead of prescribing a large single target, clinicians can ask patients where they are most ready to make a small change. A patient who cannot exercise for 30 minutes may still be able to take a 2-minute walk after lunch. A patient who resists diet counseling may still add carrots, bell pepper, or vegetable juice. A patient with poor sleep may start by shifting bedtime earlier by 5 to 10 minutes.

The most important caveat is that this was observational research. These findings should not be framed as a guaranteed life extension formula. A more balanced message is that small, combined, sustained lifestyle improvements may be associated with better lifespan, healthspan, and cardiovascular outcomes.

Migraine with aura was linked to a higher risk of ischemic stroke over about 6 years in adults aged 45 and older. Migraine without aura did not show the same signal. The most unexpected finding was in men under age 72, where migraine with or without aura was associated with a much higher stroke risk. This does not prove migraine causes stroke, but it suggests clinicians may need to ask more carefully about aura when assessing vascular risk.

Study Details

Migraine is often treated as a painful neurological condition, but it may also carry vascular clues. Prior research has linked migraine with aura to ischemic stroke, especially in younger women. This newer study is important because it focused on middle-aged and older adults, a group where stroke risk is already shaped by blood pressure, diabetes, cholesterol, smoking, atrial fibrillation, and other traditional factors.

The study was published in Neurology Open Access and used data from the REGARDS cohort, a large U.S. study designed to understand stroke risk. Researchers analyzed 11,381 people aged 45 and older who did not have stroke at the beginning of the migraine assessment period. The average age was 72, about 55% were women, and about 35% were Black participants.

Methodology

Participants were asked whether a healthcare professional had ever told them they had migraine headaches. Those who said yes were then asked whether their headaches included visual changes before the headache, which was used to classify migraine with aura.

Researchers followed participants for an average of about 6 years and looked for new ischemic strokes. They adjusted the analysis for major stroke risk factors, including age, race, income, hypertension, diabetes, smoking, atrial fibrillation, abnormal cholesterol, coronary artery disease, body mass index, and other vascular risks.

Key Findings

• Migraine with aura was associated with higher ischemic stroke risk. People with migraine aura had a 73% higher relative risk of ischemic stroke compared with people without migraine.

• Migraine without aura did not show a significant increase. The study did not find a clear stroke-risk signal in people who had migraine without aura.

• Absolute risk was still modest. Stroke occurred in about 4.7% of people with migraine aura, 3.3% of people with migraine without aura, and 3.4% of people without migraine.

• The male signal was unexpected. Men under age 72 with migraine, with or without aura, had more than a 3.5-fold higher ischemic stroke risk. This pattern was not seen in women or older men.

• The study shows association, not causation. Migraine aura may be a marker of vascular vulnerability, but the study cannot prove that migraine directly causes stroke.

Implications for Practice

For patients, this study should not create panic. A higher relative risk does not mean a stroke is likely to happen tomorrow. The more practical takeaway is that migraine with aura should be part of the conversation during routine cardiovascular risk checks, especially in midlife and older age.

For clinicians, the key question is not just “Do you have migraine?” It is also “Do you have aura?” Visual symptoms such as shimmering lights, zigzag lines, blind spots, or spreading blurry areas before a migraine may matter for vascular risk stratification. The American Migraine Foundation notes that stroke risk can rise further when migraine with aura is combined with other factors such as high blood pressure, obesity, and especially smoking.

This could shift practice toward more targeted counseling. Patients with migraine aura may benefit from aggressive management of modifiable risks: blood pressure control, smoking cessation, diabetes management, lipid optimization, physical activity, and screening for atrial fibrillation when appropriate. The study does not suggest that everyone with migraine aura needs aspirin, anticoagulation, or imaging. It suggests that aura deserves attention as part of the total risk picture.

For healthcare providers, the male finding is the most interesting part. Earlier migraine-stroke discussions often emphasized younger women, particularly when smoking or estrogen-containing contraception were involved. This study suggests middle-aged and older men with migraine may also deserve closer study and possibly more careful prevention counseling if future research confirms the signal.

A small Italian randomized trial found that patients with advanced high-grade serous ovarian cancer who followed a short-term fasting protocol during neoadjuvant chemotherapy had lower insulin levels, higher pathologic complete response rates, and longer median progression-free survival compared with patients who continued a regular diet. The results are promising but early, and fasting during cancer treatment should only be considered under medical supervision.

Study Details

Advanced ovarian cancer remains difficult to treat, especially for patients who are not candidates for immediate surgery. Many patients first receive neoadjuvant chemotherapy, usually before interval debulking surgery. The goal is to shrink the cancer, improve the chance of complete surgery, and delay progression.

This study focused on a simple but biologically interesting idea: could reducing insulin and related growth signals make chemotherapy work better? Investigators hypothesized that short-term fasting may create a metabolic environment that is less supportive of tumor growth and more favorable for chemotherapy response.

Methodology

Researchers conducted a prospective, open-label, exploratory randomized trial in patients with newly diagnosed advanced high-grade serous ovarian cancer who were not suitable for primary cytoreductive surgery.

Patients in the fasting group began fasting 36 hours before each chemotherapy cycle and continued until 24 hours after chemotherapy. During that fasting window, they consumed about 350 calories per day, with water, herbal tea, vegetable juice, and small amounts of light vegetable broth. Between chemotherapy cycles, they returned to their regular diet. Patients in the control group continued their regular diet throughout treatment.

The primary endpoint was the change in mean insulin levels, measured during the neoadjuvant chemotherapy period. Patients received three chemotherapy cycles at 21-day intervals.

Key Findings

• Lower insulin levels: At the end of neoadjuvant chemotherapy, insulin levels were significantly lower in the fasting group than in the regular-diet group.

• Higher pathologic complete response: The fasting group had a pathologic complete response rate of 58.8%, compared with 17.6% in the control group.

• Longer progression-free survival: Median progression-free survival was 38 months in the fasting group versus 24 months in the control group.

• Tolerability looked reasonable but needs caution: Overall chemotherapy toxicity did not differ significantly between groups, although grade 3/4 hematologic toxicity was numerically higher in the fasting group.

• Possible immune effect: Translational analyses suggested better anticancer immune activity in the fasting group, including lower levels of suppressor granulocytes and monocytes.

Implications for Practice

For patients, this study is important because it points to a low-cost supportive strategy that may improve chemotherapy response. But the most important practical message is caution. Cancer treatment is already physically demanding, and fasting can be risky for some patients, especially those with frailty, diabetes, poor nutrition, low body weight, kidney disease, or treatment-related nausea. This should not be attempted without an oncology team and nutrition support.

For healthcare providers, the study adds to a growing interest in metabolic modulation during cancer therapy. The signal is clinically meaningful, but the evidence remains early because this was a small pilot trial with 36 adherent patients in the final analysis. The findings should be viewed as hypothesis-generating until larger randomized multicenter trials confirm whether the benefit is real, reproducible, and safe across broader ovarian cancer populations.

The larger idea is not that fasting is a replacement for chemotherapy. It is that metabolic timing around chemotherapy may eventually become part of a more personalized supportive-care strategy. If confirmed, this could be especially relevant because it does not depend on a new expensive drug and may be feasible across many treatment settings.

A new study challenges the usual mental model of lacunar stroke. Researchers found that lacunar stroke and cerebral small vessel disease were not strongly linked to large artery narrowing from plaque.

Instead, they were strongly associated with abnormal widening, lengthening, and twisting of the basilar artery, a condition called dolichoectasia. This does not prove causation, but it may help explain why standard secondary stroke prevention does not always prevent recurrent lacunar stroke or cognitive decline in these patients.

Study Details

Lacunar stroke is a common type of ischemic stroke involving small, deep areas of the brain. It accounts for about 20% to 30% of ischemic strokes, and it is closely linked with cerebral small vessel disease. Traditionally, many clinicians have thought about ischemic stroke through the lens of blockage: plaque, narrowing, clotting, and downstream loss of blood flow.

This study asks whether that model fully explains lacunar stroke. The answer appears to be no. The researchers found little evidence that large artery stenosis was driving lacunar stroke. Instead, the stronger signal came from basilar artery dolichoectasia, meaning the artery was widened, elongated, or twisted.

The study was published online in Circulation on May 6, 2026.

Methodology

Researchers studied 229 patients with recent lacunar or mild nonlacunar ischemic stroke from the prospective Mild Stroke Study 3 cohort. Participants had clinical testing, cognitive assessment, and MRI imaging at baseline and during one year of follow-up.

About 57% of participants had lacunar stroke. About 21% had large artery stenosis, while 16% had basilar artery dolichoectasia. The team then examined whether artery narrowing or artery widening was more strongly linked with lacunar stroke, small vessel disease markers, new infarcts, and white matter injury progression.

The researchers also performed a systematic review and meta-analysis of 27 studies including more than 9500 patients with lacunar stroke, which supported the main finding that large artery stenosis showed little evidence of a causal relationship with lacunar infarction, while artery widening was more consistently linked with small vessel disease features.

Key Findings

• Large artery stenosis was associated with lower odds of lacunar stroke compared with nonlacunar stroke, with an odds ratio of 0.49.

• Large artery stenosis was not associated with cerebral small vessel disease markers or new infarcts in this analysis.

• Basilar artery dolichoectasia was strongly associated with lacunar stroke, with an odds ratio of 4.67.

• Basilar artery dolichoectasia was also linked with higher small vessel disease burden, new infarcts, and greater progression of white matter hyperintensities over one year.

• The findings support the idea that lacunar stroke may often reflect intrinsic small vessel pathology rather than the same plaque-driven mechanism seen in many larger artery strokes.

Implications for Practice

For patients, the key message is not to stop current stroke prevention treatment. Blood pressure control, smoking cessation, diabetes management, cholesterol management, physical activity, and adherence to prescribed medications still matter. High blood pressure remains one of the most important treatable stroke risk factors.

But this research suggests that lacunar stroke may need a more specific treatment strategy. If the underlying disease process is more about small vessel dysfunction and abnormal vessel structure than large artery plaque blockage, then simply applying the same treatment logic used for other ischemic strokes may not be enough.

For clinicians, the study reinforces the need to distinguish lacunar stroke from other ischemic stroke subtypes. It also supports more interest in mechanism-specific trials. One example mentioned by the researchers is LACunar Intervention Trial-3, a phase 3 study testing isosorbide mononitrate and/or cilostazol in lacunar stroke patients in the UK.

A careful note: this is still association, not proof of causation. Doctor who were not part of the study, cautioned that artery widening may be a risk marker rather than a direct cause of lacunar infarcts. More work is needed to understand the mechanism.

A cross-sectional study of nearly 2200 dementia-free Australian adults found that higher ultraprocessed food intake was associated with lower attention scores and higher estimated dementia risk, even after accounting for Mediterranean diet adherence.

The study did not find a significant link between ultraprocessed food intake and memory scores.

Study Details

Ultraprocessed foods are packaged or industrially formulated foods that often contain added sugars, refined starches, fats, flavorings, emulsifiers, and other additives. Common examples include soft drinks, sweetened beverages, packaged snacks, dairy-based desserts, and many ready-to-eat foods.

This study focused on adults aged 40 to 70 years enrolled in the Healthy Brain Project in Australia between 2016 and 2023. The participants were dementia-free at the time of the study, with an average age of 57 years. Most participants were women, White, and had higher education or socioeconomic status, which is important when thinking about how broadly the results apply.

The most consumed ultraprocessed foods in the study were dairy-based desserts and drinks, followed by soft drinks, fruit drinks, and other sweetened beverages.

Methodology

Researchers looked at participants’ usual food intake over the previous 12 months using a validated food frequency questionnaire. They estimated how much of each person’s diet came from ultraprocessed foods and also measured how closely they followed a Mediterranean-style diet.

Cognitive performance was measured using the Cogstate Brief Battery, which evaluated processing speed, visual attention, visual recognition memory, working memory, and attention. The researchers then created attention and memory composite scores. Dementia risk was estimated using the Cardiovascular Risk Factors, Aging, and Incidence of Dementia tool.

The analysis adjusted for age, sex, physical activity, smoking status, cardiometabolic disease history, body mass index, and Mediterranean diet adherence. This matters because the study tried to separate the effect of ultraprocessed foods from overall diet quality.

Key Findings

• Higher ultraprocessed food intake was associated with a higher modified dementia risk score.

• Each 10% increase in ultraprocessed food intake was linked to a measurable decrease in attention scores.

• The attention association remained significant even after adjusting for Mediterranean diet adherence.

• People whose ultraprocessed food intake made up more than 28% of total grams consumed had lower attention scores than those whose intake was 13% or less.

• No significant association was found between ultraprocessed food intake and memory scores.

Implications for Practice

For patients and families, the practical message is not that one snack causes dementia. The study shows an association, not proof of causation. Still, it adds to a growing body of evidence suggesting that diet quality may matter for brain health before dementia develops.

The most important finding is the attention signal. Attention and processing speed are daily-life functions. They affect driving, reading, work performance, medication management, and the ability to follow conversations. A diet pattern high in ultraprocessed foods may be one modifiable factor worth addressing earlier in life, especially in middle age.

For healthcare providers, this study supports including food processing level in conversations about brain health, not just calories, sugar, sodium, or fat. It may be useful to ask patients how often they consume sweetened drinks, packaged desserts, chips, ready-to-eat snacks, and heavily processed convenience foods.

The Mediterranean diet adjustment is clinically interesting. Even when researchers accounted for Mediterranean diet adherence, ultraprocessed food intake still showed an association with attention and dementia risk. That suggests clinicians may need to look at both sides of diet quality: increasing protective foods such as vegetables, legumes, fish, nuts, and olive oil, while also reducing highly processed foods.

Important Limitations

This was a cross-sectional study, so it cannot prove that ultraprocessed foods directly caused poorer attention or higher dementia risk. It captures a snapshot in time.

The study population was also not fully representative. Participants were mostly women, White, better educated, and had higher socioeconomic status. Many also had a family history of dementia. The food questionnaire relied on self-reported intake, which can introduce recall errors.

These limitations mean the findings should be interpreted as a signal that deserves further study, not as final proof.

Practical Takeaway

For people concerned about dementia prevention, this study supports a simple and realistic goal: reduce ultraprocessed foods gradually, especially sweetened drinks, packaged desserts, and snack foods. Replacing even some of these foods with less processed options may be a reasonable brain-health step.

For clinicians, the study offers another reason to discuss diet quality with middle-aged adults before cognitive symptoms appear. The focus should be practical, nonjudgmental, and specific: identify the most frequent ultraprocessed foods in a patient’s diet and help them swap one category at a time.

A new first-in-human CARE study suggests that robotic colonoscopy may be technically feasible and safe in carefully selected patients. The Triton robotic colonoscopy system achieved 100% cecal intubation in 50 patients, detected polyps at rates comparable to manual colonoscopy, and allowed successful removal of eligible polyps, while potentially reducin…

Read more

For people receiving hemodialysis, getting enough protein is a daily challenge. A 12-month quality improvement study presented at the National Kidney Foundation Spring Clinical Meeting found that giving a 15-gram liquid protein supplement at the end of each dialysis session was associated with better albumin levels, improved dialysis adequacy, and fewer…

Read more

A new study found that the hippocampus, a brain region involved in memory and learning, showed signs of sound pattern recognition and language processing in patients under general anesthesia. The finding does not mean patients were awake or aware during surgery. None of the seven patients reported explicit memory afterward. Instead, it suggests that par…

Read more

Recent research has raised a cautious signal that tattooing may be associated with increased risk of lymphoma and certain skin cancers. The current evidence is observational, meaning it can show a link but cannot prove cause and effect. For patients, this does not mean every tattoo is dangerous. For healthcare providers, it suggests tattoos should be in…

Read more

For children with acute respiratory tract infections, telemedicine visits integrated into primary care were linked with fewer antibiotic prescriptions than in-person visits, while guideline-concordant antibiotic management and short-term follow-up outcomes were similar.

Study Details

Acute respiratory tract infections are among the most common reasons ch…

Read more

Atogepant, an oral CGRP receptor antagonist already approved for migraine prevention, was linked to clinically meaningful weight loss in a 1-year open-label extension analysis. Nearly 35% of adults with migraine and BMI ≥ 25 lost at least 5% of body weight, while about 13% lost at least 10%. The finding is promising for patients with migraine and obesit…

Read more

A review of randomized controlled trials found that multimodal lifestyle interventions, including exercise, cognitive training, diet, stress reduction, sleep support, and social engagement, were associated with modest improvements in cognition among people with mild cognitive impairment or early Alzheimer’s disease.

Antiamyloid monoclonal antibodies red…

Read more

A multinational health-record study of nearly 50,000 adults with traumatic brain injury found that people who received gabapentin on the same day as their injury had better long-term outcomes in some groups.

Same-day gabapentin was associated with a 22% lower adjusted risk of durable cognitive impairment after mild TBI and a 46% lower adjusted risk of d…

Read more

A real-world study of more than 143,000 adults with obesity found that reductions in BMI were associated with lower odds of developing obesity-related cancers, especially endometrial cancer and kidney cancer.

The findings support treating obesity as a chronic disease and raise important questions about whether newer obesity medications, including GLP-1 …

Read more

A recent FDA regulatory update has moved several peptides out of the restricted “do not compound” category, signaling a potential shift toward safer, regulated access. However, these therapies are not yet approved for routine clinical use, and formal evaluation is still underway.

Study Details

Peptide-based therapies have gained attention for their potent…

Read more

A new analysis suggests that cancers with the highest death rates, such as small-cell lung cancer and pancreatic cancer, receive significantly less federal funding per death compared with cancers that have better survival outcomes.

Study Details

A recent study from the National Cancer Institute examined how federal research funding is distributed across d…

Read more

A major clinical trial suggests the factor XIa inhibitor asundexian may reduce recurrent ischemic stroke risk by about 25% without increasing major bleeding, offering a potential shift beyond traditional aspirin-based prevention strategies.

Study Details

Secondary stroke prevention has long relied on antiplatelet therapies like aspirin, which offer modest…

Read more

A new cost-effectiveness model suggests nasal epinephrine could significantly improve quality of life for people at risk of anaphylaxis by reducing needle-related anxiety, though real-world effectiveness and practical limitations still need validation.

Study Details

Anaphylaxis is a severe, potentially life-threatening allergic reaction that requires rapi…

Read more

New research suggests that nearly 1 in 5 women may develop hypertension within 7 years after their first pregnancy, with body weight and pregnancy-related complications playing a larger role than genetics.

Study Details

A recent study published in JAMA Cardiology examined how genetic predisposition to higher systolic blood pressure influences the risk of …

Read more

A large genetic study suggests that individual DNA differences may partly explain why some people lose more weight or experience more side effects on GLP1 drugs, opening the door to more personalized obesity treatment.

Study Details

GLP1 receptor agonists such as semaglutide and tirzepatide have become widely used for obesity and type 2 diabetes, but pati…

Read more